This trial is active, not recruiting.

Condition asthma
Sponsor Research in Real-Life Ltd
Collaborator Teva Pharmaceuticals USA
Start date February 2013
End date July 2014
Trial size 130248 participants
Trial identifier NCT02140541, R05812


To explore the relationship between blood eosinophil counts, asthma exacerbations and patient asthma control using a large primary care based research database

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective

Primary Outcomes

time frame: 1 year
Asthma control
time frame: 1 year

Eligibility Criteria

Male or female participants from 12 years up to 80 years old.

Inclusion Criteria: - Patient aged 12-80 at date of last eosinophil count - Asthma diagnosis at any time - Blood Eosinophil reading in patient record (numeric count expressed in µl) at least one year prior to last data extraction - Two years of continuous data Exclusion Criteria: - Any other chronic respiratory diseases - Eosinophil counts >5000/µl (outliers)

Additional Information

Official title The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils
Principal investigator David Price, Prof, MD
Description Sputum eosinophil levels have been shown to predict asthma exacerbation and inhaled corticosteroid (ICS) responsivenesss. Managing asthma based on sputum eosinophils leads to fewer exacerbations than management adhering to Global Initiative for Asthma (GINA) guidelines. However the use of sputum to measure eosinophil levels is expensive and impractical within a clinical setting. This study explores the use of blood-eosinophil levels as a clinical predictor for exacerbations and asthma control within a UK primary care dataset.
Trial information was received from ClinicalTrials.gov and was last updated in May 2014.
Information provided to ClinicalTrials.gov by Research in Real-Life Ltd.